177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT clinical trials

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

This study looks at a new type of radiation treatment called PRRT (using Lutetium-177) for certain aggressive bowel and pancreas neuroendocrine tumours. It compares this new treatment with standard care to see if it's more effective, safer, and improves patients' quality of life.